Isomorphic Labs Secures $1.2 Billion Series B Funding to Accelerate AI-Driven Drug Discovery

London-based Isomorphic Labs announced a $1.2 billion Series B round led by Thrive Capital. New investors include Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The capital will refine the IsoDDE discovery platform, fund international expansion to sites in London, Lausanne and Cambridge, and move drug candidates into clinical testing while hiring additional AI, engineering, drug-design and clinical-development experts.

Pharmaphorum

Founded in 2021 to commercialise DeepMind’s AlphaFold engine, Isomorphic builds on the 2020 breakthrough that first solved protein-folding prediction. The platform now predicts structures of proteins, RNA and DNA. In 2024 the AlphaFold team—including founder Sir Demis Hassabis, John Jumper and David Baker—received the Nobel Prize in Chemistry. A little over a year earlier, the company raised $600 million in a Series A round led by Thrive Capital and GV.

Pharmaphorum

• Sir Demis Hassabis – Founder, former DeepMind leader.

Pharmaphorum

• Investors – Thrive Capital, GV, Alphabet, MGX, Temasek, CapitalG, UK Sovereign AI Fund.

Pharmaphorum

• Pharma collaborators – Johnson & Johnson, Novartis and Eli Lilly, whose joint research agreements are valued at several billions of dollars.

Pharmaphorum

• Series B: $1.2 billion.

Pharmaphorum

• Series A: $600 million (total raised $1.8 billion).

Pharmaphorum

• Research collaborations: Johnson & Johnson, Novartis, Eli Lilly—collectively worth billions.

Pharmaphorum

• IsoDDE capabilities: third-generation engine extending AlphaFold’s predictive reach to any biological molecule.

Pharmaphorum

Isomorphic’s leadership described the round as a “massive vote of confidence” in its AI-first drug-design approach and emphasized that the company’s methodology has been proven “fundamentally sound.” The firm also noted that the financing will enable the transition of its pipeline into clinical testing and support a broad hiring push across its three global sites.

Pharmaphorum

The infusion of capital underscores growing investor belief that AI can compress drug-discovery timelines and lower development costs. By pairing deep-learning predictions with large-scale pharma partnerships, Isomorphic aims to accelerate the translation of molecular insights into therapeutic candidates, potentially reshaping conventional R&D models.

Pharmaphorum

• “This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development,” — Sir Demis Hassabis, Founder, Isomorphic Labs

Pharmaphorum

• “Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential,” — Sir Demis Hassabis, Founder, Isomorphic Labs

Pharmaphorum

• “This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.” — Isomorphic Labs, Official Statement

Pharmaphorum

The company plans to initiate clinical trials for its leading candidates within the next 12 months, expand hiring in AI and clinical teams, and deepen collaborations with its pharma partners as it scales the IsoDDE platform globally.

Pharmaphorum